213 related articles for article (PubMed ID: 15746049)
1. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
2. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
[TBL] [Abstract][Full Text] [Related]
6. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
[TBL] [Abstract][Full Text] [Related]
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
8. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.
Karanikas V; Soukou F; Kalala F; Kerenidi T; Grammoustianou ES; Gourgoulianis KI; Germenis AE
Clin Immunol; 2008 Nov; 129(2):230-40. PubMed ID: 18789878
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
[TBL] [Abstract][Full Text] [Related]
10. [Generation of HER2 specific, HLA-A24 restricted CTLs derived from gastric cancer patients].
Mimura K; Kono K; Sugai H; Miyagawa N; Omata H; Fujii H; Matsumoto Y
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1802-4. PubMed ID: 14619524
[TBL] [Abstract][Full Text] [Related]
11. Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.
Hirohashi Y; Torigoe T; Hirai I; Tamura Y; Nakatsugawa M; Inoue Y; Kanaseki T; Kamiguchi K; Ikeda H; Sasaki A; Yamanaka N; Sato N
Exp Mol Pathol; 2010 Feb; 88(1):128-32. PubMed ID: 19818766
[TBL] [Abstract][Full Text] [Related]
12. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
13. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
16. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
17. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
Ichiki Y; Hanagiri T; Takenoyama M; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Sugaya M; Yasuda M; So T; Sugio K; Yasumoto K
Lung Cancer; 2005 May; 48(2):281-9. PubMed ID: 15829330
[TBL] [Abstract][Full Text] [Related]
18. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
[TBL] [Abstract][Full Text] [Related]
19. Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors.
Wang M; Johansen B; Nissen MH; Thorn M; Kløverpris H; Fomsgaard A; Buus S; Claësson MH
Cancer Lett; 2007 Jun; 251(1):86-95. PubMed ID: 17182178
[TBL] [Abstract][Full Text] [Related]
20. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH; Pedersen LO; Becker JC; Straten PT
Cancer Res; 2001 Feb; 61(3):869-72. PubMed ID: 11221872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]